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by interrogating our expression data, we were able to show 
that each molecular group possessed expression phenotypes 
suggesting different cellular differentiation: astrocytic in one 
group and oligodendroglial in the second. Informed by this, 
we were able to identify CCND1, CSPG4, and PDGFRA 
as immunohistochemical targets which could distinguish 
between molecular groups. Our data suggest that the cur-
rent histological classification of glioneuronal tumours does 
not adequately represent their underlying biology. Instead, 
we show that there are two molecular groups within glioneu-
ronal tumours. The first of these displays astrocytic differen-
tiation and is driven by BRAF mutations, while the second 
displays oligodendroglial differentiation and is driven by 
FGFR1 mutations.
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Abstract Glioneuronal tumours are an important cause  of 
treatment-resistant epilepsy. Subtypes of tumour are often 
poorly discriminated by histological features and may be 
difficult to diagnose due to a lack of robust diagnostic tools. 
This is illustrated by marked variability in the reported fre-
quencies across different epilepsy surgical series. To address 
this, we used  DNA methylation arrays and RNA sequenc-
ing to assay the methylation and expression profiles within 
a large cohort of glioneuronal tumours. By adopting a class 
discovery approach, we were able to identify two distinct 
groups of glioneuronal tumour, which only partially cor-
responded to the existing histological  classification. Fur-
thermore, by additional molecular analyses, we were able 
to identify pathogenic mutations in BRAF and FGFR1, spe-
cific to each group, in a high proportion of cases. Finally, 
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Epilepsy is the most common serious chronic neurologi-
cal condition of childhood, which has long-term effects on 
health and quality of life. In the UK, the incidence of epi-
lepsy in children between 0 and 7 years of age has been 
estimated at 71-116/100,000 persons-years-at-risk [12]. 
In a separate study, the cumulative incidence of epilepsy 
rose to 8.4/1000 by the age of 23 [9]. Structural abnormali-
ties of the brain are frequently observed in patients with 
intractable childhood epilepsy [1]. Of these abnormalities, 
brain tumours represent the second most common cause of 
seizures [5]. This is particularly true for low-grade corti-
cal glioneuronal tumours, the most prevalent of which are 
ganglioglioma (GG) and dysembryoplastic neuroepithelial 
tumour (DNET).
Glioneuronal tumours pose a significant diagnostic prob-
lem. A number of subtypes are recognised on histological 
grounds, but in clinical practice are often poorly discrimi-
nated between by their histological features. Moreover, a 
high proportion of cases possess non-specific histological 
appearances that preclude confident classification. Poor 
inter-observer correlation is commonplace, particularly for 
ganglioglioma and DNET, where there is unexplained and 
marked geographical variability across surgical series, which 
suggests marked variability in diagnostic practice (Online 
Resource 1, reviewed in [16]).
It is unclear how many distinct entities are present within 
the spectrum of glioneuronal tumours, and a number of sub-
types have been proposed [3]. However, these classifications 
are based on a subjective assessment of histological features 
that may not be representative of underlying tumour biology. 
Robust biologically informed classifications are necessary 
to facilitate effective characterisations of tumour subtypes.
A number of the previous studies have identified patho-
genic abnormalities in a proportion of glioneuronal tumours. 
The most notable of these are the presence of BRAF-V600E 
mutations in a subset of ganglioglioma and FGFR1 abnor-
malities in a portion of DNETs [13, 14]. However, BRAF-
V600E mutations and copy number changes have also been 
reported in DNETs, and there is a general lack of consensus 
regarding the genetic background of these tumours [4, 7, 
10]. A common theme among the previous studies is that 
they recruited and segregated cases according to classical 
histological features. However, as mentioned previously, this 
does not necessarily reflect the underlying biology and may 
be prone to inaccuracies in classification. In light of this, 
we hypothesised that a molecular classification, based on 
biological similarity, may align more closely with patho-
genic features.
To approach this problem, we have used molecular tech-
niques to characterise the most prominent glioneuronal 
tumours, including those with non-specific histology. We 
have taken a class discovery approach, to classify tumours 
according to their underlying molecular profiles and fea-
tures. From this, we have been able to identify two distinct 
molecular groups within glioneuronal tumours. Moreover, 
we have been able to identify genetic abnormalities that 
are strongly enriched within each of the molecular groups 
unveiled. Finally, we have determined cell-type specific 
phenotypes that define each group. Here, we present a com-
prehensive genomic classification and characterisation of 
epilepsy-associated glioneuronal tumours, which we favour 
over the conventional histological approaches.
Materials and methods
Case recruitment
Surgical cases were principally retrieved from the Great 
Ormond Street Hospital (GOSH) archives. 111 patients diag-
nosed with a ganglioglioma, DNET, or glioneuronal tumour 
between 1991 and 2015 were identified and corresponding 
diagnostic formalin fixed paraffin embedded (FFPE) sections 
were retrieved. The histology for these cases was reviewed 
by an experienced paediatric neuropathologist (TSJ), accord-
ing to current WHO diagnostic criteria [11]. Cases were 
categorised into three groups according to their histological 
features: Ganglioglioma, DNET, and glioneuronal tumour of 
uncertain histologic subtype (GNT NOS). The latter group 
included non-specific histological variants, atypical tumours, 
and those that appeared as a mix of histological types.
Additional cases were acquired from the Children’s Can-
cer and Leukaemia Group (n = 24) (CCLG Project Number 
2015BS03). These cases were categorised histologically in 
the same manner as our GOSH cohort. Detailed histologi-
cal review was not performed for these cases due to limited 
diagnostic slides.
For control cases in this study, we retrieved archival tem-
poral cortex from patients that had undergone resections for 
hippocampal sclerosis (HS). Prior to inclusion, this material 
was assessed and confirmed to be free of tumour and other 
structural pathology.
Clinical review
Clinical data were available for 69 patients within our GOSH 
cohort, including follow-up data for 60 of these patients 
that had presented with epilepsy. Data were acquired from 
archived patient records and included sex, age at first sei-
zure, seizure duration prior to surgery, age at surgery, pres-
ence of tumour on postoperative MRI, and seizure status at 
1 year postoperatively and last follow-up. Statistical analyses 





RNA was extracted from frozen archival material from cases 
for which it was available. Prior to extraction, haematoxy-
lin and eosin-stained cryosections were prepared to assess 
tumour content. Tumour content was graded 1–4 as follows: 
1—no evidence of tumour; 2—focal areas of tumour; 3—
majority is tumour but with some non-neoplastic compo-
nents; and 4—extensive tumour/tumour comprised entire 
section. Cases where the cryosection was graded 1–2 were 
excluded. Extraction of total RNA was carried out using the 
miRNeasy Mini Kit according to the manufacturer’s instruc-
tions. Eluted RNA was subjected to quality control by anal-
ysis on a NanoDrop 1000 spectrophotometer and samples 
with a 260/280 ratio lower than 1.8 were excluded. Further 
quality control was carried out using the Agilent Bioana-
lyzer platform and samples with an RNA Integrity Num-
ber (RIN) lower than 4 were excluded. Library preparation 
and RNA sequencing were carried out by UCL Genomics. 
Libraries were prepared using non-strand specific Illumina 
TruSeq Sample Preparation Kits. Libraries were sequenced 
at a depth of 15 million reads per sample on the Illumina 
NextSeq 500 platform. Resultant FASTQ files were aligned 
using TopHat and Cufflinks software packages to produce 
Binary Alignment Map (BAM) files for subsequent analysis.
Analysis of expression data
Bioinformatic analysis of expression data was primarily car-
ried out in R. Read counts were generated from BAM files 
using the GenomicRanges package. Consensus clustering 
was carried out using the ConsensusClusterPlus package 
according to the Ward method for hierarchical clustering. 
Cases were clustered using the top 5000 most variable genes 
across the cohort (tumours and controls) as determined by 
median absolute deviation. Prior to analysis, cases were clus-
tered in an unsupervised manner into two groups and those 
that clustered with controls were excluded as likely possess-
ing low tumour content. In subsequent clustering, to identify 
the optimum number of clusters, the k corresponding to the 
first downwards inflection in cumulative distribution func-
tion was used (Online Resource 2). Identification of differ-
entially expressed genes was performed using DESeq2. For 
differential expression analysis, a false discovery adjusted 
p value (q value) less than 0.1 was considered significant.
Gene set enrichment analysis (GSEA) was carried out 
using the GSEA software [15] (available at http://software.
broadinstitute.org/gsea/index.jsp). Genes were pre-ranked 
in DESeq2 by Wald statistic before GSEA analysis against 
custom gene sets for neural-cell-type specific expression pat-
terns. Neural-cell-type specific gene sets were constructed 
from the top 150 genes up-regulated in each cell type as 
reported by Zhang et al. [19].
DNA preparation
DNA was extracted from FFPE tissue using the Maxwell 16 
FFPE Tissue LEV DNA Purification Kit in conjunction with 
the Maxwell 16 Research Instrument according to the manu-
facturer’s instructions. Subsequently, 250 ng eluted DNA 
was subjected to bisulphite conversion, while the remainder 
was stored at − 80 °C for TAm-seq assay. Bisulphite con-
version was performed using the Zymo EZ DNA Methyla-
tion-Gold Kit. Bisulphite converted DNA was additionally 
treated using the Infinium FFPE DNA Restore Kit.
DNA for target capture panel sequencing was extracted 
using the QIAamp DNA FFPE Tissue Kit. DNA was quanti-
fied using Qubit dsDNA High Sensitivity Assay Kit with the 
Qubit 2.0 fluorometer. Subsequently, analysis by TapeSta-
tion 2200 using the genomic DNA ScreenTape assay was 
performed to determine the degree of fragmentation.
450k methylation analysis
Bisulphite converted and restored DNA was assayed on the 
Illumina HumanMethylation450 BeadChip array platform, 
in accordance with the Infinium HD Assay protocol. Pro-
cessed arrays were scanned using an Illumina IScan array 
scanner to generate IDAT output files.
Bioinformatic analysis of methylation data was performed 
in R. Data was read in using Minfi, and normalised with 
the included subset-quantile within array normalisation 
method. Probes located on the X and Y chromosomes were 
excluded. In addition, probes located within 50 bp of an 
SNP, probes known to cross-hybridise, probes with a minor 
allele frequency > 5%, and probes that had failed to hybrid-
ise in > 30% of samples in the cohort were excluded.
Consensus clustering of methylation data was carried out 
using the ConsensusClusterPlus package according the Ward 
method. Cases were clustered using the top 10,000 most 
variable CpGs across the cohort as determined by median 
absolute deviation. To identify the optimum number of clus-
ters, k corresponding to the first downwards inflection in 
cumulative distribution function was used (Online Resource 
2).
Copy number analysis on 450k methylation data was car-
ried out using the conumee R package. LogR ratio thresh-
olds of ± 0.15 were used as a cutoff to determine gains and 
losses.
Gene set enrichment analysis of methylation data was 
carried out using the gsameth function in the missMethyl 
R package. Differentially methylated positions (DMPs) 
between Group 1 and Group 2 tumours were identified 
using the dmpFinder function in Minfi. This list of DMPs 
was then assayed for over-representation of CpGs associated 
with genes specified by each gene set. Gene sets were con-
structed from the top 150 genes up-regulated in astrocytes 
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and oligodendrocyte precursors, as reported by Zhang et al. 
[19].
TAm‑seq
Primers specifically targeting CTNNB1 Exon 3, BRAF-
V600, HIST1H3B, H3F3A, IDH1, and IDH2 were designed. 
Sequencing was performed using a protocol adapted from 
Weaver et al. [18]. After two separate rounds of PCR, result-
ing amplicons consisted of the genomic region of interest 
flanked by adapter sequences, a 5′ sample-specific barcode, 
and Illumina adapter sequences complementary to the flow 
cell. Samples were pooled, purified, and sequenced on the 
Illumina MiSeq platform. Reads were aligned to the human 
genome using bwa mem (v0.7.13-r1126) and variants were 
detected by VarScan mpileup2snp (v2.3) with a minimum 
variant allele frequency of 0.5%. Regions were failed if 
fewer than 100 reads were observed using bamreadcount. 
Variants were considered valid if present in either of dupli-
cate sequencing reactions with at least 50 reads in the variant 
allele.
Capture panel sequencing
A panel covering a total of 78 genes, either recurrently 
altered in paediatric cancers or clinically actionable in adult 
cancers was used [6]. Customised biotinylated probes (Nim-
blegen SeqCap EZ library) capture a total of 311 kb for the 
detection of single nucleotide variants, short indels, copy 
number variants, and structural rearrangements. Libraries 
were prepared using the KAPA Hyper kit and SeqCap EZ 
adapters. Following fragmentation, DNA was end-repaired, 
A-tailed and ligated with indexed adapters. DNA was ampli-
fied over 6 PCR cycles where 200 ng starting material was 
available. 10 PCR cycles were performed where less than 
200 ng was used. Samples were multiplexed and hybrid-
ised twice overnight on consecutive days using 1 µg of total 
pre-capture library DNA to the DNA baits targeting the 78 
panel genes. 5 PCR cycles were performed between hybrid-
isations to enrich the captured product. After the second 
hybridisation, unbound capture baits were washed away and 
the remaining hybridised DNA was amplified over 12 PCR 
cycles. PCR products were purified using AMPure beads 
and quantified using the KAPA Quantification Q-PCR Kit. 
Sequencing was performed using the Illumina MiSeq plat-
form (75 bp paired-end reads and v3 chemistry) according 
to the manufacturer’s instructions.
Primary analysis was performed using the MiSeq 
Reporter Software (v2.5.1), generating nucleotide sequences 
and base quality scores in FASTQ format. Resulting 
sequences were aligned against the human reference genome 
build GRCh37/hg19 to generate binary alignment maps and 
variant call files. Secondary analysis was performed using 
an in-house Molecular Diagnostics Information Manage-
ment System to generate QC, variant annotation, visualise 
data, and generate reports. All potential mutations, structural 
variants, and CNVs were visualised using the Integrative 
Genomics Viewer. In the absence of germline DNA, com-
mercial genomic DNA G147A (Promega) was used as a 
baseline control to filter out common SNPs. In addition, all 
variants identified were screened against Exome Aggrega-
tion Consortium (ExAC) and dbSNP databases, and were 
excluded if their variant allele frequency across the popula-
tion was > 0.0001 with 0 homozygous calls.
Immunohistochemistry
Immunohistochemistry was performed using a Leica Bond-
Max autostainer according to manufacturer’s protocol F. 
Cases were stained for CCND1 (1/40, CellMarque–241R), 
CSPG4 (1/100, Atlas–HPA002951) and PDGFRA (1/200, 
Santa Cruz–sc-338). Immunohistochemistry against H3 
K27M (1:1500, Millipore – ABE419) was performed in 
the same manner. Positive controls for all antibodies were 
included (CCND1-Mantle cell lymphoma; CSPG4-Large 
intestine, PDGFRA-Gastrointestinal stromal tumour; H3 
K27M-Diffuse midline glioma, H3 K27M-mutant). Stain-
ing for CCND1 and PDGFRA was undertaken at UCL 
Advanced Diagnostics.
Results
Clinical and histopathological features of the cohort
From a cohort of 111 archival cases retrieved from the 
GOSH archives, we identified 99 glioneuronal tumours 
upon histological review. The 12 remaining cases repre-
sented non-glioneuronal tumours that had been flagged dur-
ing initial cohort collection due to the presence of the term 
“glioneuronal” in the comments of their archival pathology 
reports. The most common histological subtypes were gan-
glioglioma (44/99–44%), followed by DNET (18/99–18%). 
However, the remaining 37/99 (37%) of cases could not be 
definitively categorised due to a lack of distinctive histologi-
cal features and were classified as “glioneuronal tumours of 
uncertain histologic type” (GNT NOS). Summary data for 
the histological features of the GOSH cohort, excluding 1 
case with extremely limited material, are shown in Table 1. 
We obtained 24 additional tumours from the CCLG. 20 of 
these represented cortical glioneuronal tumours, comprising 
16 ganglioglioma, 1 DNET, and 3 GNT NOS. The remain-
ing four cases could not be confidently classified, due to 
extremely limited diagnostic material, and were excluded.
Clinical data were available for 69 GOSH patients for 
whom histological review had been carried out (32 GG, 14 
Acta Neuropathol 
1 3
DNET, 23 GNT NOS) (Table 2). 60 (87%) of these pre-
sented with seizures at diagnosis (25 GG, 13 DNET, 22 
GNT NOS). This corresponded to 78% of ganglioglioma, 
93% of DNET, and 96% of GNT NOS. These differ-
ences were not statistically significant by Fisher’s exact 
test (p = 0.125). Seizure follow-up data were available 
for all 60 of these patients. Mean follow-up duration was 
25.3 months (range 1–96 months). Mean age at seizure 
onset was 55.8 months (range 3–188 months) for gangli-
oglioma, 78 months (range 24–168 months) for DNET, 
and 41.1 months (0.5–180 months) for GNT NOS. When 
assessed by ANOVA, there was no significant difference 
in age at seizure onset between the three groups (ANOVA 
F = 2.226, p = 0.117). Postoperatively, Fisher’s exact test 
showed that there was no significant difference in seizure 
freedom at 1 year or last follow-up across the three histologi-
cal categories. 16/25 (64%) ganglioglioma were seizure free 
at 1 year, compared to 7/13 (54%) of DNET and 12/22 (54%) 
GNT NOS. At last follow-up, 15/25 (60%) ganglioglioma 
were seizure free, compared to 6/13 DNET (46%) and 12/22 
(54%) GNT NOS. In total, 35/60 (58%) of patients were sei-
zure free at 1 year postoperatively. This fell to 33/60 (55%) 
at last follow-up.
The following features were also analysed against seizure 
freedom at 1 year postoperatively and last follow-up: seizure 
duration prior to surgery, age at first seizure, age at surgery, 
and the presence of residual tumour on postoperative MRI. 
For all factors excluding residual tumour, we found no sig-
nificant association at either 1 year or last follow-up. We 
identified a significant association between residual tumour 
and seizure outcome  at 1 year (p = 0.046, Fisher’s exact 
test). Residual tumour was associated with a poorer rate of 
seizure freedom, although this effect was small and a large 
proportion of patients without residual tumour continued 
to experience seizures. 13/27 (48%) of patients with resid-
ual tumour were seizure free compared to 17/27 (63%) of 
patients without residual tumour. However, when assayed 
against seizure outcome at last follow-up, this association 
did not retain significance.
Table 1  Summary of 
histological features for 98 
glioneuronal tumours
Histological features Ganglioglioma (n = 43) DNET (n = 18) GNT NOS (n = 37)
Specific glioneuronal element 0% (0/43) 89% (16/18) 0% (0/37)
Floating neurons 2% (1/43) 72% (13/18) 11% (4/37)
Dysplastic neurons 100% (43/43) 0% (0/18) 13% (5/37)
Anaplasia 5% (2/43) 5% (1/18) 0% (0/37)
Oligodendrocyte-like cells 26% (11/43) 94% (17/18) 43% (16/37)
Neoplastic astrocytic component 98% (42/43) 11% (2/18) 59% (22/37)
Calcification 60% (26/43) 22% (4/18) 40% (15/37)
Necrosis 0% (0/43) 0% (0/18) 0% (0/37)
Microvascular proliferation 9% (4/43) 11% (2/18) 3% (1/37)
Rosenthal fibres 19% (8/43) 0% (0/18) 3% (1/37)
Eosinophilic granular bodies 49% (21/43) 0% (0/18) 3% (1/37)
Inflammation 51% (22/43) 0% (0/18) 19% (7/37)
Extravascular CD34 + (n = 76) 80% (28/35) 23% (3/13) 82% (23/28)
Cortical dysplasia (n = 59) 16% (4/25) 0% (0/9) 12% (3/25)
Table 2  Summary of clinical features for the 69 patients with glioneuronal tumours for which clinical data was available
Clinical features Ganglioglioma DNET GNT NOS
Gender (n = 69) 19 M/13F 6 M/8F 11 M/12F
Presented with seizures (n = 69) 25 (n = 32) 13 (n = 14) 22 (n = 23)
Age 1st seizure (n = 60) (months) 56 (3–188) (n = 26) 78 (24–168) (n = 13) 24 (0.5–180) (n = 21)
Age surgery (n = 62) (months) 118 (20–201) (n = 26) 130 (41–188) (n = 13) 101 (17–212) (n = 23)
Seizure duration (n = 59) (months) 68 (8–162) (n = 25) 52 (1–146) (n = 13) 61 (5–165) (n = 21)
Residual post-op tumour (n = 55) 9 (n = 23) 7 (n = 12) 12 (n = 20)
Seizure free at 1 year (n = 60) 16 (n = 25) 7 (n = 13) 12 (n = 22)
Seizure free at last follow-up (n = 60) 15 (n = 25) 6 (n = 13) 12 (n = 22)
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RNA expression and DNA methylation identify two 
major groups of glioneuronal tumour
To investigate the presence of distinct biological entities 
within the spectrum of glioneuronal tumours, we utilised 
consensus clustering to undertake a class discovery approach 
to our RNA sequencing and methylation data.
For the RNA sequencing cohort, after quality control 
to remove cases with low tumour content and poor-quality 
RNA, 19 tumours (7 GG, 6 DNET, 6 GNT NOS) and 7 con-
trols were analysed. After inspecting the cumulative distri-
bution function plot, we found that the clustering configura-
tion that explained the most biological variability within the 
cohort represented three groups. The first of these consisted 
entirely of control cases (n = 7). The next, referred to as 
RNA Group 1, consisted of 5 ganglioglioma and 5 GNT 
NOS (n = 10). The final group, referred to as RNA Group 
2, consisted of 6 DNET, 2 ganglioglioma, and 1 GNT NOS 
(n = 9). Clustering data for these cases are shown in Fig. 1a.
For the methylation profiling cohort, 65 tumours (34 GG, 
11 DNET, 20 GNT NOS) and 6 controls were analysed. 
Recapitulating our observations from the RNA sequencing 
cohort, upon inspection of the cumulative distribution plot, 
we found that the clustering configuration that explained 
the most biological variability within the cohort represented 
three groups. The first of these consisted of all controls plus 
28 tumours (13 GNT NOS, 13 GG, 2 DNET). The next, 
referred to as Methyl Group 1, consisted of 19 gangli-
oglioma, 1 DNET, and 1 GNT NOS (n = 21). The final 
group, referred to as Methyl Group 2, consisted of 8 DNET, 
2 ganglioglioma, and 6 GNT NOS (n = 16). Clustering data 
for these cases are shown in Fig. 1b.
Our RNA and methylation cohorts were largely inde-
pendent. 12 cases were subjected to both assays; however, 
only six of these had successfully clustered away from con-
trols in both. These were six tumours that corresponded to 
RNA Group 2 in the expression data clustering, which also 
clustered with Methyl Group 2 during the methylation data 
clustering.
Molecular subtype associates with age at seizure onset
Having identified two distinct groups, we decided to ana-
lyse clinical features against molecular classification in 
the same manner as for histological classification. Seizure 
follow-up data were available for 28 cases that had been 
molecularly classified either by RNA or by methylation 
profiling (14 Group 1, 14 Group 2) (Table 3). Mean follow-
up duration was 19.9 months (range 1.5–63 months). 12/14 
(86%) Group 1 tumours presented with seizures, compared 
to 11/14 (79%) Group 2 tumours. We found no significant 
association between molecular group and seizure freedom 
at either 1 year postoperatively or last follow-up. 7/12 (58%) 
patients with Group 1 tumours and 5/11 (45%) patients with 
Group 2 tumours were seizure free at both 1 year and last 
follow-up. We also found no significant difference in seizure 
duration prior to surgery or age at surgery. However, we 
observed a striking difference in age at onset of seizures 
Fig. 1  Glioneuronal tumours cluster into two groups, which are only 
partially consistent with histology, according to their expression and 
methylation profiles. a Consensus clustering heatmap of 19 tumours 
(7 GG 6 DNET, 6 GNT NOS) and 7 controls. Cases are clustered 
according to the top 5000 most variably expressed genes. Group 1 
consisted of 5 GG and 5 GNT NOS (n = 10). Group 2 consisted of 2 
GG, 6 DNET, and 1 GNT NOS (n = 9). b Clustering heatmap of 65 
tumours (34 GG, 11 DNET, 20 GNT NOS) and 6 controls. Cases are 
clustered according to the top 10,000 most variably methylated CpGs. 
Group 1 consisted of 19 GG, 1 DNET and 1 GNT NOS (n  =  21). 
Group 2 consisted of 2 GG, 8 DNET, and 6 GNT NOS (n = 16)
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between the two groups (Fig. 2). Patients with Group 1 
tumours possessed a mean age at first seizure of 30.2 months 
(SE = 13.9) compared to 87.5 (SE = 17.3) for those with 
Group 2 tumours (t = − 2.6, p = 0.017).
Pathogenic mutations can be found in most tumour 
cases and segregate according to molecular subtype
To determine the genetic background of the two groups 
within the methylation and RNA sequencing cohorts, we 
decided to investigate the presence of pathogenic mutations 
by two methods.
45 individual samples that had segregated from controls 
in the RNA sequencing and methylation cohorts underwent 
tagged amplicon sequencing (TAm-seq) and were assayed 
against a panel of six genes (Fig. 3a). These represented 26 
RNA/Methyl Group 1 and 19 RNA/Methyl Group 2 tumours. 
Samples for which mutations were identified are detailed in 
Table 4. We observed abnormalities in 13/26 (54%) Group 
1 tumours, of which 12 (46%) possessed a BRAF-V600E 
mutation. These were four cases from our RNA sequencing 
cohort and eight from our methylation cohort. One case with 
a BRAF-V600E mutation also possessed a CTNNB1-G34E 
mutation. The remaining mutation positive case possessed 
an H3F3A-K27M mutation. On histology review, this case 
was a ganglioglioma and the mutation was confirmed by 
immunohistochemistry. Of the 19 RNA/Methyl Group 2 
tumours assayed, we identified no mutation positive cases. 
All variants detected are predicted to be pathogenic and have 
been previously described.
We also assayed the 28 tumours that had failed to segre-
gate from controls in our methylation cohort by TAm-seq. 
We observed BRAF-V600E mutations in 15 (54%) of these 
cases. These mutation positive cases represented eight gan-
gliogliomas and seven GNT NOS. We identified no other 
mutations in these tumours.
Having identified a number of mutation positive cases 
by TAm-seq, we decided to expand the scope of mutation 
Table 3  Summary of clinical 
features for 28 tumours 
classified by expression or 
methylation profile
For the age data, the values are the mean and range
Clinical features Group 1 Group 2
Gender (n = 28) 8 M/6F 7 M/7F
Presented with seizures (n = 28) 12 (n = 14) 11 (n = 14)
Age 1st seizure (months) (n = 28) 30 (5–180) (n = 14) 87 (23–180) (n = 14)
Age surgery (months) (n = 28) 99 (20–192) (n = 14) 141 (46–188) (n = 14)
Seizure duration (months) (n = 28) 67 (5–158) (n = 14) 55 (1–165) (n = 14)
Residual post-op tumour (n = 20) 7 (n = 9) 6 (n = 11)
Seizure free at 1 year (n = 23) 7 (n = 12) 5 (n = 11)
Seizure free at last follow-up (n = 23) 7 (n = 12) 5 (n = 11)
Fig. 2  Molecular classifica-
tion associates with age at first 
seizure. a When assayed against 
current histological classifica-
tion, there is no significant 
association with age at first 
seizure (ANOVA F = 2.226, 
p = 0.117). b When tumours 
are classified according to their 
molecular profiles Group 1 
tumours present with seizures 




screening using target capture sequencing against an exist-
ing panel of 78 genes developed at the Institute of Cancer 
Research. 32 individual samples from our RNA sequenc-
ing and methylation cohorts underwent mutation screening 
(Fig. 3b). These represented 20 RNA/Methyl Group 1 and 
12 RNA/Methyl Group 2 tumours. Samples for which muta-
tions were identified are detailed in Table 5. We observed 
abnormalities in 18/20 (90%) of Group 1 tumours, of which 
13 (65%) possessed a BRAF-V600E mutation. These were 
five cases from our RNA sequencing cohort and eight from 
our methylation cohort. Six cases with BRAF-V600E muta-
tions possessed additional mutations. The remaining five 
mutation positive Group 1 tumours lacking a BRAF muta-
tion possessed an FGFR1, NF1, ARID1B, HIST1H3B, and 
ATM mutations, respectively.
We identified mutations in all 12 Group 2 tumours that 
were assayed by target capture DNA sequencing. Of these, 
9/12 (75%) possessed an FGFR1 mutation. These FGFR1 
mutations consisted of 6 tandem duplications, 1 exon 18 
inversion, and 1 instance each of A334T and L567E substi-
tutions. The latter two of these are not previously described 
to our knowledge. These cases represented 5 that had been 
in both our RNA and methylation cohorts and 4 from our 
methylation cohort alone. 4 Group 2 tumours that were 
positive for an FGFR1 mutation also possessed additional 
abnormalities. These were mutations in ATM, TP53, AKT1, 
and MAP2K2. The remaining three cases lacking an FGFR1 
abnormality were 1 case possessing HRAS, APC, and WT1 
mutations, 1 case possessing ARID1A and ACVR1 muta-
tions, and 1 case with MYCN and CDK4 amplifications. 
While all cases were screened against commercial genomic 
DNA, and ExAC and dbSNP databases, it should be noted 
that all variants identified by this assay that are non-recur-
rent across the cohort may represent private SNPs rather 
than pathogenic mutations.
Copy number changes are frequent, but are rarely 
recurrent
Copy number status can be estimated from methylation 
data, and copy number abnormalities have previously been 
reported in glioneuronal tumours. Therefore, we decided 
to investigate the presence of copy number abnormalities 
across the two molecular groups we had identified. In total, 
we assayed 65 tumours and found copy number abnormali-
ties in 17 (26%) (Table 6). Histologically, these represented 
nine ganglioglioma, three DNET, and five GNT NOS. When 
labelled according to molecular classification, these were 7 
Group 1 tumours and 4 Group 2 tumours. In addition, we 
identified copy number abnormalities in six tumours that 
had not classified robustly with either group away from 
controls. We identified copy number abnormalities in all 
chromosomes except 3 and 16. Losses were present in chro-
mosomes 1, 2, 4, 8, 9, 10, 11, 12, 13, 14, 17, 19, and 22. 
Gains were present in chromosomes 1, 5, 6, 7, 8, 10, 11, 
12, 15, 18, 19, 20, and 21. The most common abnormali-
ties across the cohort were gain of chromosome 7 (n = 7) 
and loss of chromosome 13 (n = 6). Chromosome 22 loss 
was also observed in 4 cases. No copy number change was 
significantly associated with molecular or histological clas-
sification. In addition, neither BRAF nor FGFR1 mutation 
status associated with copy number changes.
The molecular subtypes show different patterns 
of cytological differentiation
To test the hypothesis that the two molecular groups were 
composed of distinct cell types, we used gene set enrichment 
Fig. 3  Majority of glioneuronal tumours possess pathogenic muta-
tions; BRAF and FGFR1 mutations are highly selective for groups 
identified by consensus clustering. a Tagged amplicon sequenc-
ing against 45 tumours assayed for mutations in CTNNB1, BRAF, 
HIST1H3B, H3F3A, IDH1, and IDH2. 14/45 (31%) possessed a 
mutation, of which the most common was BRAF-V600E in 12/26 
(46%) Group 1 tumours. No BRAF mutations were detected in Group 
2 tumours. Mutations in CTNNB1, H3F3A, and IDH1 were detected 
in 4 cases, 1 of which was BRAF-V600E positive. b Target capture 
DNA sequencing against 32 tumours assayed for a panel of 78 genes. 
30/32 (94%) possessed mutations. The most common abnormalities 
were BRAF-V600E, affecting 13/20 (65%) Group 1 tumours, and 
abnormalities in FGFR1 in 1/20 (5%) Group 1 and 9/12 (75%) Group 
2 tumours. Mutations in ATM, TP53, AKT1, MAP2K2, HRAS, APC, 
WT1, ARID1A, ACVR1, MYCN, and CDK4 were also detected both 




analysis to assay our RNA sequencing cohort for differential 
enrichment of genes, whose expression is associated with 
specific  neural cell types (Table 7). When compared against 
controls, we observed enrichments in Group 1 tumours cor-
responding to astrocytic, microglial, and endothelial pheno-
types (p > 0.05). When we compared Group 2 tumours to 
controls, we identified enrichments for endothelial, micro-
glial, and oligodendrocyte precursor phenotypes (p > 0.05). 
When we compared Group 1 tumours vs Group 2 tumours 
directly, we identified enrichments for astrocytic and neu-
ronal phenotypes in Group 1 tumours. Group 2 tumours were 
enriched for endothelial and all oligodendroglial lineage 
phenotypes, with the oligodendrocyte precursor phenotype 
demonstrating the strongest score.
We were able to perform a similar gene set enrichment 
analysis on the two molecular groups within our methyla-
tion cohort, with the aim of confirming differential enrich-
ment of astrocyte and oligodendrocyte precursor phenotypes 
between groups. When we compared Group 1 vs Group 2 
tumours, we observed differential enrichments for both 
oligodendrocyte precursor and astrocyte gene sets within 
the list of differentially methylated sites between groups 
(p > 0.005) (Online Resource 3).
Having observed an oligodendrocyte precursor enrich-
ment in Group 2 tumours as part our gene set enrichment 
analysis, we hypothesised that immunohistochemistry 
directed against oligodendrocyte precursors could distin-
guish the tumour groups. We selected CCND1, CSPG4, and 
PDGFRA as targets due to their association with this cell 
type (Fig. 4). Five cases from each group were randomly 
selected and stained for all three targets (total n = 10). For 
CCND1, we noted a striking difference in staining between 
groups. In Group 1 tumours, only a small proportion of 
tumour cells were weakly stained, compared to a majority 
of tumour cells possessing moderate-to-strong staining in 
Group 2 tumours (Fig. 4a–d). This pattern was repeated for 
PDGFRA, for which we observed a thin rim of cytoplasmic/
membranous staining in the majority of tumour cells within 
Table 4  Summary of mutation positive cases identified by tagged amplicon sequencing
Sample Histology Mol. group Mutation Depth Mutation allele frequency Average Additional mutations
Duplicate 1 Duplicate 2
GNT03 GG 1 BRAF-V600E 207 8% N/A 8% N/A
GNT21 GG 1 BRAF-V600E 226 7% 8% 8% N/A
GNT29 GG 1 BRAF-V600E 163 8% N/A 8% N/A
GNT35 GG 1 BRAF-V600E 1455 28% 32% 30% N/A
GNT40 GNT NOS 1 BRAF-V600E 726 23% 25% 24% N/A
GNT48 GG 1 BRAF-V600E 71 1% 1% 1% N/A
GNT51 GG 1 BRAF-V600E 2948 23% 25% 24% N/A
GNT52 GNT NOS 1 BRAF-V600E 79 7% 6% 7% CTNNB1-G34E
GNT16 GG 1 BRAF-V600E 6370 17% 20% 19% N/A
GNT01 GG 1 BRAF-V600E 6277 26% 23% 25% N/A
GNT05 GG 1 BRAF-V600E 4400 18% 20% 19% N/A
GNT17 GG 1 BRAF-V600E 2197 17% 18% 18% N/A
GNT18 GG 1 H3F3A-K27M 3047 36% 24% 30% N/A
GNT94 GG N/A BRAF-V600E 707 11% 13% 12% N/A
GNT60 GG N/A BRAF-V600E 282 9% 8% 9% N/A
GNT69 GG N/A BRAF-V600E 852 14% 15% 15% N/A
GNT76 GG N/A BRAF-V600E 343 18% 11% 15% N/A
GNT27 GG N/A BRAF-V600E 1403 19% 20% 20% N/A
GNT95 GNT NOS N/A BRAF-V600E 1149 13% 15% 14% N/A
GNT81 GNT NOS N/A BRAF-V600E 1482 14% 15% 15% N/A
GNT39 GNTNOS N/A BRAF-V600E 5016 33% N/A 33% N/A
GNT96 GG N/A BRAF-V600E 2519 25% 25% 25% N/A
GNT87 GNT NOS N/A BRAF-V600E 1097 11% 12% 12% N/A
GNT89 GG N/A BRAF-V600E 1299 16% 16% 16% N/A
GNT50 GNT NOS N/A BRAF-V600E 3185 30% 28% 29% N/A
GNT54 GG N/A BRAF-V600E 558 17% N/A 17% N/A
GNT92 GNT NOS N/A BRAF-V600E 1694 18% 19% 19% N/A
GNT44 GNT NOS N/A BRAF-V600E 196 34% 8% 21% N/A
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Group 2 tumours, while only neurons were stained in Group 
1 tumours (Figs. 4i–l,  5). For both CCND1 and PDGFRA, 
staining within Group 2 tumours was most prominent within 
the “oligodendrocyte-like” cell population often described 
within DNETs. CSPG4 displayed a less striking difference 
between tumour groups. Staining was slightly more promi-
nent in Group 2 tumours, in particular with moderate-to-
strong staining in the cell membrane of a proportion of “oli-
godendrocyte-like” cells and the neuropil. However, staining 
was highly variable between cases. In contrast, within Group 
1 tumours, staining was evident only in neurons and a frac-
tion of tumour cells (Fig. 4e–h).
To validate the utility of these targets in distinguish-
ing tumours, cases were reviewed and segregated into 
two groups by an independent pathologist (WM), blinded 
to molecular classification and prior histological diagno-
sis (Online Resource 4). CCND1 was the best performing 
stain, for which all cases (10/10) were segregated concord-
antly with molecular classification. 9/10 cases stained with 
CSPG4 were segregated in agreement with molecular clas-
sification. The remaining case, a histologically difficult case 
with limited tumour content and extensive calcification, 
could not be confidently segregated. PDGFRA performed 
similarly, with 8/10 cases segregated in a manner concord-
ant with molecular classification. The remaining two cases 
were two Group 2 tumours that were segregated alongside 
Group 1 tumours.
Table 5  Summary of mutation positive cases identified by target capture DNA sequencing
Sample Histology Mol. group Depth BRAF/FGFR1 Additional mutations
GNT03 GG 1 682 BRAF-V600E (12%) ARID1B-Q717K (49%)
GNT15 GG 1 432 BRAF-V600E (12%)
GNT22 GG 1 37 BRAF-V600E (15%) CTNNB1-A39V (10%)
GNT16 GG 1 698 BRAF-V600E (20%) ASXL1-R235W (42%)
GNT21 GG 1 264 BRAF-V600E (22%)
GNT51 GG 1 677 BRAF-V600E (24%) ASXL1-S1428P (51%)
GNT40 GNT NOS 1 1051 BRAF-V600E (25%)
GNT17 GG 1 518 BRAF-V600E (26%)
GNT35 GG 1 557 BRAF-V600E (32%) FGFR2-Q779A (46%), CDNK2A/B Del,
ATM-R2461C (20%)
GNT29 GG 1 20 BRAF-V600E (50%)
GNT45 GG 1 14 BRAF-V600E (50%)
GNT18 GG 1 708 BRAF-V600E (1%) H3F3A-K27M (29%)
GNT09 GG 1 185 BRAF-V600E (4%)
GNT37 DNET 2 953 FGFR1-A334T (32%)
GNT31 DNET 2 258 FGFR1-L567E (36%) ATM-R1039L (9%)
GNT07 GNT NOS 2 711 FGFR1 duplication
GNT23 DNET 1 414 FGFR1 duplication MLL2-R3596W (43%)
GNT33 DNET 2 410 FGFR1 duplication
GNT10 DNET 2 714 FGFR1 duplication
GNT43 DNET 2 1153 FGFR1 duplication TP53-R282Q (47%), N235S (44%)
GNT38 DNET 2 1021 FGFR1 duplication AKT1-E117 Del (37%)
GNT14 GNT NOS 2 173 FGFR1 duplication
GNT24 DNET 2 488 FGFR1 e18 Inversion MAP2K2-S127L (46%)
GNT36 GG 2 1568 N/A HRAS-A134V (48%), APC-E1209K (44%),
WT1-G60R (38%)
GNT13 GG 1 974 N/A NF1-L585 Frameshift (54%)
GNT49 GG 2 791 N/A ARID1A-158S (72%), ACVR1-V435 Del (42%)
GNT11 GG 1 7 N/A
GNT08 GG 1 1251 N/A ARID1B-H92L (38%)
GNT42 GG 1 607 N/A HIST1H3B-M121T (47%)
GNT30 GG 2 39 N/A MYCN + CDK4 Amplified




Glioneuronal tumours are poorly distinguished by their his-
tological features and a proportion of cases possess unin-
formative histological appearances that preclude confident 
classification. Interestingly, 37% of the cases within our 
GOSH cohort did not fit well within the current histologi-
cal subtypes. However, this problem is not unique to our 
practice or diagnostic criteria as poor inter-observer corre-
lation is commonplace in published studies, particularly for 
ganglioglioma and DNET, for which there is unexplained 
and marked geographical variability across surgical series 
(Online Resource 1) [16]. In this context, improving the 
consensus for histopathological diagnosis forms part of an 
on-going debate, with a focus particularly directed towards 
increased use of molecular genetic assays [2]. Our data sug-
gest that most glioneuronal tumours fall within two major 
groups as defined by expression profiling and DNA meth-
ylation. These groups are only partially consistent with the 
existing histological classification, and each includes a num-
ber of tumours for which traditional histological examina-
tion proved insufficient. This, therefore, suggests that the 
histological appearance of these tumours may not robustly 
reflect their underlying biology. Because of this, we favour 
the development of classification strategies based on biologi-
cal rather than histological similarity.
While the majority of tumours could be segregated by 
molecular classification into two groups, a number could not 
be distinguished cleanly from controls. This was particularly 
true for our methylation analysis, in which 28/65 tumour 
samples clustered with control temporal cortex. While it is 
Table 6  Summary of copy 
number abnormalities found in 
17/65 glioneuronal tumours
In Mol. Group, N/A are cases that clustered with controls during consensus clustering
Sample Histology Mol. group Losses Gains
GNT42 GG 1 8, 13
GNT57 GG 1 7
GNT58 GG 1 5, 7
GNT16 GG 1 2, 13, 19, 22 20
GNT17 GG 1 1
GNT35 GG 1 9, 10, 11, 13, 14, 22
GNT47 GNT NOS 1 1,7
GNT59 DNET N/A 4, 10, 12, 13, 17 7, 19
GNT04 GG N/A 7, 12, 19, 20
GNT27 GG N/A 13
GNT39 GNT NOS N/A 5, 7, 8, 11, 12, 15, 18, 20
GNT46 GG N/A 10
GNT50 GNT NOS N/A 9
GNT02 GNT NOS 2 9, 13
GNT07 DNET 2 21
GNT25 GNT NOS 2 22
GNT37 DNET 2 22 5, 6, 7, 10, 13
Table 7  Gene set enrichment analysis for neural-cell-type specific 
gene sets
ES enrichment score. NES normalised enrichment score. For these 
scores, the highest and lowest scores are the most strongly enriched 
within each of the groups being compared, respectively. MO mature 
oligodendrocyte. NFO  newly formed oligodendrocyte. OPC oligo-
dendrocyte precursor cell
Gene Set Size ES NES p value q value
Group 1 vs Control
 ASTROCYTE 149 0.68 2.98 < 0.0005 < 0.0005
 MICROGLIA 148 0.62 2.72 < 0.0005 < 0.0005
 ENDOTHELIA 148 0.59 2.57 < 0.0005 < 0.0005
 MO 149 − 0.73 − 3.31 < 0.0005 < 0.0005
 NFO 148 − 0.69 − 3.13 < 0.0005 < 0.0005
 NEURON 148 − 0.53 − 2.40 < 0.0005 < 0.0005
 OPC 149 − 0.32 − 1.47 0.005 0.005
Group 2 vs Control
 ENDOTHELIA 149 0.71 3.06 < 0.0005 < 0.0005
 MICROGLIA 148 0.61 2.64 < 0.0005 < 0.0005
 OPC 149 0.61 2.64 < 0.0005 < 0.0005
 ASTROCYTE 149 0.39 1.68 < 0.0005 0.001
 MO 149 − 0.63 − 2.71 < 0.0005 < 0.0005
 NEURON 148 − 0.61 − 2.53 < 0.0005 < 0.0005
 NFO 148 − 0.46 − 1.96 < 0.0005 < 0.0005
Group 1 vs Group 2
 ASTROCYTE 149 0.61 2.74 < 0.0005 < 0.0005
 NEURON 148 0.40 1.76 < 0.0005 < 0.0005
 MO 149 − 0.37 − 1.64 < 0.0005 < 0.0005
 NFO 148 − 0.52 − 2.28 < 0.0005 < 0.0005
 ENDOTHELIA 149 − 0.52 − 2.32 < 0.0005 < 0.0005
 OPC 149 − 0.72 − 3.22 < 0.0005 < 0.0005
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possible that these may represent a third group of tumours, 
it seems more likely that these simply represent those with 
low tumour content and consequently weaker methylation 
profiles, particularly given the architectural pattern of some 
glioneuronal tumours that intermix with normal cells. This 
is supported by the identification of BRAF mutations in a 
number of cases that failed to segregate, which likely repre-
sent Group 1 tumours when taken together with the observed 
enrichment of BRAF mutations within this group. An alter-
native explanation for the failure to segregate, given that all 
Fig. 4  Immunohistochemistry against CCND1 (a–d), CSPG4 (e–h), 
and PDGFRA (i‑l) in Group 1 and Group 2 tumours. CCND1 dis-
played the most striking difference between tumour groups, staining 
a minority of tumour cells within Group 1 tumours, in contrast to a 
majority in Group 2 tumours. CSPG4 was more variable between 
cases within groups and therefore less robust, staining neurons in 
Group 1 tumours, compared to a proportion of “oligodendrocyte-
like” cells and the neuropil in Group 2 tumours. For PDGFRA we 
observed a thin rim of membranous/cytoplasmic staining in the 
majority of tumour cells within Group 2 tumours, while only neurons 
were stained in Group 1 tumours. Scale bars = 100 μm
Fig. 5  Immunohistochemistry against PDGFRA in a Group 1 and Group 2 tumour. a PDGFRA staining is largely absent in Group 1 tumours. b 
Thin rim of staining can be observed in the tumour cells of Group 2 tumours (arrows). Scale bars = 100 μm
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DNA was derived from FFPE material, may be that these 
samples represent those with significant DNA degradation, 
distorting their methylation profiles, and making them dif-
ficult to distinguish. As degradation is likely to be uneven 
across the genome, this may leave specific sites relatively 
intact, explaining why we were able to detect mutations in a 
large proportion of these tumours.
In each molecular group, we identified a high proportion 
of cases for which pathogenic mutations could be identified 
(Online Resource 5). Group 1, containing a relatively high 
proportion of tumours with a ganglioglioma-like appearance, 
is enriched for BRAF-V600E mutations. Group 2 tumours, 
with approximately half of the tumours displaying a DNET-
like appearance, are enriched for FGFR1 mutations. This 
is partially consistent with the previous reports of muta-
tions within glioneuronal tumours. Qaddoumi et al. recently 
identified BRAF mutations in 53% of ganglioglioma, with 
V600E mutations accounting for 35% of cases, and FGFR1 
mutations in 82% of DNETs [13]. In addition, Rivera et al. 
were able to identify FGFR1 mutations in 58% of DNETs 
[14]. However, BRAF mutations and copy number abnor-
malities have also been reported in DNETs, complicating 
the genetic background of these tumours and making con-
sensus difficult [4, 7, 10]. A specific feature of these studies 
is that they segregated tumours according to histological 
classification, which our data suggest may not be reliable or 
reflective of the underlying biology. Having taken a novel 
and unbiased approach to classification, our findings suggest 
that BRAF and FGFR1 mutations are highly specific within 
glioneuronal tumours to each of the two molecular tumour 
groups we have identified, and may be well suited as mark-
ers for distinguishing them from one another. The specificity 
of these mutations to each group also supports the robust-
ness of our consensus clustering approach. It is curious 
that a proportion of cases seemingly lack these mutations. 
However, given the low average allele frequency of these 
mutations across the cohort, it is possible that they may be 
present at such low frequencies in some cases that they may 
not necessarily be detected without multiple assays to avoid 
under-sampling. In cases possessing mutations, the rela-
tively low and variable mutation allele frequencies across 
the cohort are likely explained by the architecture of these 
tumours, a large proportion of which present as nodules of 
abnormal cells admixed with cells that appear histologically 
normal. Alternatively, it may be that only specific popula-
tions of tumour cells harbour the mutation. Supporting this 
hypothesis, mutant BRAF expression in ganglioglioma has 
previously been reported to associate with the neuronal com-
ponent [8]. For cases where mutations cannot be detected, 
classification may be achievable through genomic profiling 
by methylation arrays, or by the use of immunohistochemi-
cal stains such as CCND1, which we found displayed the 
most robust and consistent difference in staining between 
the two molecular groups.
In addition to the identification of mutations in each 
tumour group, we were able to demonstrate enrichment for 
specific cell types. Group 1 was enriched most prominently 
for an astrocytic phenotype, while Group 2 was enriched for 
an oligodendrocyte precursor phenotype, indicating contrast-
ing cellular differentiation between the two tumour groups. 
The latter of these was validated by our immunohistochemi-
cal assays against the oligodendrocyte precursor-associated 
proteins CCND1, CSPG4, and PDGFRA. This novel finding 
may potentially indicate differing cells of origin for each of 
Fig. 6  Molecular classifica-
tion of glioneuronal tumours. 
Glioneuronal tumours can be 
classified into two groups based 
on their molecular profiles. 
These groups are only partially 
consistent with existing histo-
logical classification. Group 1 
tumours are enriched for BRAF 
mutations and possess an astro-
cytic expression phenotype. 
In addition, they present with 
seizures significantly earlier. In 
contrast, Group 2 tumours are 
enriched for FGFR1 mutations 




the tumour types. However, it is also a possibility that these 
phenotypes represent a downstream effect of the mutations 
enriched within each group. BRAF-V600E activity has pre-
viously been associated with astrocyte hyper-proliferation, 
while FGFR1 activity is associated with inhibition of oli-
godendrocyte precursor differentiation [17, 20]. If these 
mutations occur in a common precursor and drive tumour 
development by influencing differentiation direction, then 
this may explain why Group 1 tumours, enriched for BRAF-
V600E mutations display an astrocytic expression pheno-
type, while Group 2 tumours display an oligodendrocyte 
precursor enrichment alongside frequent FGFR1 mutations.
While we observed no difference in seizure outcome 
between groups for patients presenting with epilepsy, we 
noted a significant difference in the age at which seizures 
first arise. This may suggest a difference in the early clini-
cal course of these tumours, and supports the hypothesis 
that the two groups identified by expression and methylation 
profiling are indeed distinct biological entities rather than 
categorisation by chance.
In summary, we present a new model for the classifica-
tion of glioneuronal tumours, based on biological similar-
ity rather than subjective histological examination (Fig. 6). 
We have shown that glioneuronal tumours can be classified 
into two groups by either their expression or methylation 
profiles. This is particularly useful for cases, where the his-
tological features are uninformative and confident diagnosis 
is precluded (GNT NOS). Our classification is supported 
by the identification of BRAF and FGFR1 mutations, which 
are strongly associated with each group, and the differential 
enrichment of distinct neural cell phenotypes: astrocytic for 
Group 1 and oligodendroglial for Group 2. This biologi-
cally guided classification should help towards addressing 
the marked diagnostic variability seen across surgical series 
and may assist in refining future cohorts for which accurate 
segregation of biological entities is necessary.
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